BiotechTube
Home/Pipeline/IFx-Hu2.0

IFx-Hu2.0

Not Specified

Not SpecifiedPipeline Asset

Key Facts

Indication
Not Specified
Phase
Not Specified
Status
Pipeline Asset
Company
TuHURA Biosciences

About TuHURA Biosciences

TuHURA Biosciences is a Phase 3 immuno-oncology company with a mission to develop therapeutics that overcome primary and acquired resistance to cancer immunotherapies. Founded in 2019, the company has aggressively built a diversified pipeline through internal R&D and the strategic 2025 acquisition of Kineta, Inc., which added the clinical-stage VISTA inhibitor TBS-2025. TuHURA's strategy focuses on accelerating development via regulatory pathways for unmet needs in both solid tumors (e.g., Merkel cell carcinoma) and hematological cancers (e.g., AML), aiming to broaden the efficacy of existing treatments like checkpoint inhibitors.

View full company profile

Therapeutic Areas

OncologyImmuno-oncology

Other Not Specified Drugs

DrugCompanyPhase
New TCM FormulationsChina SXT PharmaceuticalsResearch / Pre-clinical
Long-acting LeronlimabCytoDynPreclinical
Collaborative Program with FerringPharmaBiomeResearch
Lighthouse Pilot ProductCipheromePilot
Nitric Oxide + Collagen DeliveryJellagenResearch
UndisclosedAutheraPre-clinical
mRNA Therapeutics Platform ApplicationLupagenResearch
PHYRAGOHanda PharmaceuticalsApproved
TASCENSO ODTHanda PharmaceuticalsApproved
AxulinHousey Pharmaceutical Research LaboratoriesCommercial
PBI-04711Phoenix BiotechnologyPre-clinical
Immunology ProgramIgnite BiomedicalDiscovery